The Train It Right Life
The Train It Right Life is about more than fitness — it is about building a life you choose. Hosted by IFBB Pro and entrepreneur Alicia Bell, this show dives deep into discipline, hustle, mindset, setbacks, and successes. From behind-the-scenes in bodybui
Listen to latest episode
Follow Our Podcast
Recent Episodes
Episode 25 – The Train It Right Life – Coming Back Stronger, Finding Myself After Set Backs, Weight Gain and Losing Friends
In this raw and real episode, I open up about the journey of rebuilding after life's unexpected detours.I share my personal experiences with setbacks, navigating weight gain, losing friendships, and ultimately finding my way back to a stronger, more authentic version of myself. If you have ever faced challenges that made you question your path, … Continue reading Episode 25 – The Train It Right Life – Coming Back Stronger, Finding Myself After Set Backs, Weight Gain and Losing Friends
Episode 24 – The Train It Right Life – Self Love
Episode 24 - The Train It Right Life - Self Love Alicia Bell IFBB Figure Pro is back with another episode of the podcast about self love, fuck boys and online coaching! What a better time to return with some podcast love then Valentines Day Weekend!
Episode 23- The Train It Right Life – Live In The Now
Episode 23- The Train It Right Life - Live In The Now! Happy New Year Everyone! It's time to Live in the now! Thanks for your support, listening, reviewing, sharing and subscribing! It's time to make 2021 great!
Episode 22- The Train It Right Life – Im Back!
It has been a hot minute! Sorry for my absence! But Im back! Heres a short episode about life, where I have been, covid lockdowns and staying on track during this tough time.
Health Canada approves Zolgensma®, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA)1
Health Canada approves Zolgensma®, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA)1 * SMA is a rare genetic disease that leads to progressive muscle weakness, paralysis and, when left untreated in its most severe form, permanent ventilation or death for most patients by age 22,3* Zolgensma (onasemnogene abeparvovec) is approved for the treatment of pediatric SMA patients with 3 or fewer copies of the SMN2 gene, or infantile-onset SMA1* Zolgensma is designed to address the genetic root cause of SMA by replacing the missing or defective SMN1 gene to halt disease progression1 DORVAL, QC, Dec. 16, 2020 /CNW/ – Novartis Pharmaceuticals Canada Inc. is pleased to announce that Health Canada has approved Zolgensma® (onasemnogene abeparvovec) an adeno-associated virus (AAV) vector-based gene therapy indicated for the treatment of pediatric patients with 5q spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene and 3 or fewer copies of SMN2 gene; or infantile-onset SMA1. Zolgensma is a gene therapy designed to address the genetic root cause of SMA by replacing the missing or defective SMN1 gene1. It is administered during an intravenous (IV) infusion, delivering a new working copy of the SMN1gene into a patient’s cells, halting disease progression and restoring production of SMN protein1. “SMA can be a devastating diagnosis for families to receive. Without treatment, many children would not be able to meet important developmental milestones like lifting their head, sitting or walking. Even breathing and swallowing can become difficult in the severe, infant-onset form of this disease,” said Dr. Hugh McMillan, Pediatric Neurologist at the Children’s Hospital of Eastern Ontario in Ottawa. “The approval of Zolgensma in Canada offers children an opportunity to maximize their developmental potential from this one-time therapy. The decision to treat based upon weight may allow children diagnosed slightly later to also benefit from this therapy.” “When I first started diagnosing SMA, I couldn’t have imagined that we would see such scientific advancements,” said Dr. Nicolas Chrestian, Chief of Paediatric Neurology, specialized in neuromuscular disorders at Centre Hospitalier Mère Enfant Soleil, Université Laval in Québec City. “Zolgensma offers, in a single dose, the possibility of halting the progression of this degenerative condition that can rob children of regular developmental milestones.” In Canada each year, approximately one in 10,000 babies are born with SMA, a rare, genetic neuromuscular disease caused by a defective or missing SMN1 gene3. Without a functional SMN1 gene, infants with SMA lose the motor neurons responsible for muscle functions such as breathing, swallowing, speaking and walking2. Left untreated, muscles become progressively weaker2,3. In the most severe form, this eventually leads to paralysis and ultimately permanent ventilation or...
POWERED BY BLUBRRY
